论文部分内容阅读
目的:探讨左氧氟沙星联合利福平对肺结核患者血清降钙素原、IL-15及INF-γ水平的影响。方法:选择我院收治的肺结核患者72例,随机分为对照组和实验组,每组各36例,所有患者均给予利福平以及肝泰乐口服治疗,实验组在对照组基础上给予左氧氟沙星治疗。观察并比较两组患者治疗前后血清TCP,IL-15及INF-γ水平的变化情况以及临床效果。结果:与治疗前相比,两组患者治疗后TCP,IL-15及INF-γ水平均下降,差异具有统计学意义(P<0.05);与对照组相比,实验组患者治疗后TCP,IL-15及INF-γ水平较低,差异具有统计学意义(P<0.05);实验组患者治疗总有效率(97.22%)高于对照组(86.11%),差异具有统计学意义(P<0.05)。结论:左氧氟沙星联合利福平能够降低肺结核患者TCP、IL-15、INF-γ水平,提高临床疗效,对临床有指导意义。
Objective: To investigate the effect of levofloxacin plus rifampin on the levels of procalcitonin, interleukin-15 and INF-γ in patients with pulmonary tuberculosis. Methods: Seventy-two patients with tuberculosis admitted to our hospital were randomly divided into control group and experimental group with 36 cases in each group. All patients were treated with rifampicin and Gantrez orally. The experimental group was given levofloxacin treatment. The changes of serum TCP, IL-15 and INF-γ levels before and after treatment and the clinical effects were observed and compared between the two groups. Results: Compared with those before treatment, the levels of TCP, IL-15 and INF-γ decreased after treatment in both groups (P <0.05). Compared with the control group, the levels of TCP, (P <0.05). The total effective rate of treatment group (97.22%) was higher than that of control group (86.11%), the difference was statistically significant (P < 0.05). Conclusion: Levofloxacin combined with rifampin can reduce the levels of TCP, IL-15 and INF-γ in patients with pulmonary tuberculosis and improve the clinical efficacy, which is of clinical significance.